LIAISON® Chagas
Automated CLIA assay for the qualitative determination of antibodies to Tripanosoma cruzi in human serum and plasma samples including specimens collected post-mortem.
Background
Chagas disease, is a zoonosis caused by Trypanosoma cruzi (T. cruzi). Endemic in Central and Latin American countries, the disease also has a growing presence in non-endemic countries through the migration of people, becoming an emerging health problem. Current estimates report around 18 million people worldwide affected by this chronic, systemic, parasitic infection, of which about 8 million people are resident in Latin America. Up to 30% of patients will develop heart damage, and up to 10% will develop damage to their oesophagus, colon or autonomic nervous system, or all of these, in the late chronic phase of the disease.
Why use LIAISON® Chagas
Increased specificity vs potential cross-reacting species.
Reduced cross reactivity vs related protozoan / other parasitic diseases (like Malaria, Visceral Leishmaniasis, Leishmaniasis) which can cause false positives.
To be used on
Designed for both specialty and routine tests, LIAISON® XL immunoassay analyzer helps your laboratory handle multiple patients and tests simultaneously. LIAISON® systems are trustworthy, intuitive and deliver automated continuous operation with minimal user intervention. The result is reduced turnaround time, optimal cost management and unmatched growth potential.
LIAISON® XL
Designed for large laboratories. Fuse the benefits of high throughput and high sensitivity within a powerful and fully automated system that can seamlessly connect to facilitate Total Laboratory Automation.
More details about our diagnostic solutions
Login to Dialog for additional resources
Login to our repository for instructions for use and user manuals, assay information, protocols and much more.